[Principles of treatment of different forms of alcoholic liver disease: A review].

The review considers the principles of treatment of various forms of alcoholic liver disease from the point of view of the evidence base and clinical recommendations. The main therapy for severe alcoholic hepatitis is systemic glucocorticosteroids, their effect on survival is increased by the addition of antioxidants (N-acetylcysteine, ademethionine). The effect of ademetionine on the life expectancy of patients with alcoholic cirrhosis of Child-Pugh class A and B has been proven. The treatment of patients with mild forms of alcoholic liver disease is not well developed, and the evidence base for most of the drugs used is modest.

Аdеmethionine in the treatment of fatigue in liver diseases: a systematic review.

AIM: To systematize the published data on the treatment of hepatogenic fatigue with аdеmethionine. MATERIALS AND METHODS: Search was performed using databases PubMed, EMBASE, Embase®, Medline®, eLIBRARY.ru, published in 1952-2018. RESULTS: 16 articles were found on the use of аdеmethionine in liver diseases and the assessment of the dynamics of the symptom of fatigue, including 1 double-blind, randomized, placebo-controlled study, 3 open randomized studies; most of the works were multicenter open observation programs. The studies included 3238 patients (of which 2820 were included in the final data analysis) and a wide range of liver diseases: alcoholic liver disease, nonalcoholic fatty liver disease, primary biliary cholangitis, primary sclerosing cholangitis, cirrhosis of different causes, viral hepatitis, drug-induced liver injury. Different doses, routes of administration of аdеmethionine and the duration of the course were used. CONCLUSION: Ademethionine, regardless of the route of administration, is effective in the treatment of fatigue due to different liver disease in the short and long term. The dose-dependent effect of the drug and the possibility of maintaining post-effect after end of the treatment course should be assumed, but this requires further study in randomized clinical trials.

[Clinical features of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in geriatric practice in Saint Petersburg.]

Objective - to identify the clinical features of inflammatory bowel disease (IBD) in elderly and senile patients in St. Petersburg. A retrospective analysis of medical charts of 208 patients over 60 years old with inflammatory bowel diseases (IBD) was carried out: 60% of them with ulcerative colitis (UC), 40% with Crohn's disease (CD). The control group consisted of 867 patients aged up to 60 years (UC- 524 patients, 60,4%; CD - 343 patients, 29,6%). Concomitant cardiovascular diseases were detected in 87% of patients, broncho-pulmonary - in 25%, diseases of the bones and joints - in 35%, pathology of the kidneys and urinary tract - in 26,5%, and liver - in 44%. Debut and recurrent IBD were often accompanied (33,6%) by a worsening of somatic pathology (versus 8,7% in other age groups of patients). It's took longer to verify diagnosis of IBD in older patients, than in patients of young and middle ages. Patients with distal localization of the pathological process (proctitis and left-sided colitis) prevailed among patients with UC, the inflammatory form of the disease dominated in patients with CD.

[A new system of specialized gastroenterological care to patients with inflammatory bowel diseases in St. Petersburg].

AIM: To substantiate the effectiveness of the set-up center in the early detection of patients with inflammatory bowel diseases (IBD) and in its organization and implementation of current therapeutic programs. MATERIALS AND METHODS: The therapeutic activity of the specialized medical care system set up in St. Petersburg for patients with IBD (ulcerative colitis (UC) and Crohn's disease (CD)), which is based on a multifunctional inflammatory bowel disease center at City Clinical Hospital Thirty-One, was analyzed. RESULTS: The effective work of the center could reduce time for verification of the diagnosis of UC from 6.4 +/- 1.4 to 3.6 +/- 0.8 months and CD from 28.6 +/- 6.7 to 15.3 +/- 4.2 months, respectively; decline the annual number of patients with moderate and severe UC from 73.4 to 53.6 and CD from 66.7 to 47%, and also set up a centralized system for all required types of current therapeutic and diagnostic care for these patients. CONCLUSION: The establishment of the St. Petersburg Center for the diagnosis and treatment of inflammatory bowel diseases could develop and realize in practice a new closed-loop urban system for the early detection and notification of IBD patients, the organization and rendering of individual effective therapeutic-and-prophylactic care.